AI use case

ISM001-055 Phase IIa Trial — AI-Designed Therapeutic Achieves Clinical Milestone

Insilico Medicine's AI-designed therapeutic ISM001-055, an idiopathic pulmonary fibrosis treatment targeting the TNIK pathway, achieved positive Phase IIa clinical trial results…

Browse catalog

At a glance

Core facts from this catalog record. Primary narrative lives in the hero above; full raw fields follow in the next section.

Company/Organization: Insilico Medicine
Industry: Biotechnology
Location: New York

Record fields

Every column from the source row, in stable order. URLs open in a new tab.

Title

ISM001-055 Phase IIa Trial — AI-Designed Therapeutic Achieves Clinical Milestone

Content

Insilico Medicine's AI-designed therapeutic ISM001-055, an idiopathic pulmonary fibrosis treatment targeting the TNIK pathway, achieved positive Phase IIa clinical trial results. ISM001-055 was designed and brought to clinical trials using agentic AI workflows, representing one of the most advanced examples of AI-designed drugs reaching clinical validation. The drug was discovered using Insilico's generative chemistry platform and validated through AI-powered clinical trial design. The positive Phase IIa results validate the end-to-end AI drug discovery approach, from target identification through molecule generation to clinical development. This milestone positions AI-designed drugs as viable commercial therapeutics.

URL

https://www.prnewswire.com/news-releases/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055-a-novel-first-in-class-drug-treatment-for-idiopathic-pulmonary-fibrosis-ipf-designed-using-generative-ai-302251732.html

Continue exploring AI deployments in the catalog.

Back to use cases